Novo Nordisk (NVO) Debt to Equity (2006 - 2026)
Novo Nordisk (NVO) debt to equity from Mar 31, 2006 to Mar 31, 2026. The current Novo Nordisk (NVO) debt to equity is 72.09%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Novo Nordisk (NVO)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 67.49% | -5.79% |
| 2024 | 71.64% | +182.66% |
| 2023 | 25.34% | -17.94% |
| 2022 | 30.88% | -18.00% |
| 2021 | 37.66% | +130.30% |
| 2020 | 16.35% | +110.09% |
| 2019 | 7.78% | +683.52% |
| 2018 | 0.99% | -70.79% |
| 2017 | 3.40% | +572.23% |
| 2016 | 0.51% | -77.86% |
| 2015 | 2.28% | +27.85% |
| 2014 | 1.79% | +253.79% |
| 2013 | 0.51% | -58.96% |
| 2012 | 1.23% | -45.98% |
| 2011 | 2.28% | -62.14% |
| 2010 | 6.02% | +54.89% |
| 2009 | 3.88% | -44.69% |
| 2008 | 7.02% | +65.73% |
| 2007 | 4.24% | -15.69% |
| 2006 | 5.03% | N/A |
Comparison Novo Nordisk (NVO) debt to equity with competitors
Novo Nordisk (NVO) debt to equity is 72.09%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| SNY | Sanofi | 27.50% | -61.85% |
| BIIB | Biogen Inc | 33.72% | -53.23% |
| JNJ | Johnson & Johnson | 67.73% | -6.04% |
| PFE | Pfizer Inc | 71.50% | -0.81% |
| AZN | Astrazeneca plc | 71.66% | -0.59% |
| GILD | Gilead Sciences Inc | 94.30% | +30.81% |
| GSK | GSK Plc | 106.74% | +48.08% |
| MRK | Merck & Co Inc | 107.06% | +48.52% |
| LLY | Lilly(Eli) & Company | 139.02% | +92.85% |
| MDCX | MDCorp | 176.75% | +145.19% |
| MDCXW | Medicus Pharma Ltd warrant | 176.75% | +145.19% |
| GRFS | Grifols SA | 177.15% | +145.75% |
| BMY | Bristol-Myers Squibb Company | 219.95% | +205.12% |
| AMGN | AMGEN Inc | 623.75% | +765.29% |
| OGN | Organon & Company | 948.95% | +1216.41% |